Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine.
Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine.
复制标题
新型纳米乳佐剂疫苗诱导针对耐甲氧西林金黄色葡萄球菌感染的全身和粘膜免疫
DOI：
10.2147/ijn.s91529
复制
发表时间：
2015
影响因子：
8
通讯作者：
Zeng H
中科院分区：
文献类型：
--
作者：
Sun H;Wei C;Liu B;Jing H;Feng Q;Tong Y;Yang Y;Yang L;Zuo Q;Zhang Y;Zou Q;Zeng H
革兰氏阳性细菌病原体耐甲氧西林金黄色葡萄球菌（MRSA）可引起血流、内皮组织、呼吸道、培养证实的皮肤或软组织中的感染。目前还没有有效的疫苗，预计在不久的将来也不会有。还迫切需要能够引发全身和粘膜免疫应答的有效疫苗。在这里，我们报道了一种新型水包油纳米乳液佐剂疫苗，其含有MRSA重组蛋白抗原、Cremophor EL-35®作为表面活性剂和丙二醇作为助表面活性剂。该纳米乳疫苗的平均粒径为31.34±0.49 nm，具有良好的蛋白结构完整性、蛋白特异性和室温1年的稳定性。肌内免疫和鼻黏膜免疫试验表明，该疫苗可提高Balb/c小鼠肌内免疫和C57小鼠鼻内免疫后血清中免疫球蛋白（IG）G及其相关亚类（如IgG 1、IgG 2a和IgG 2b）和伊加的特异性免疫应答。此外，该纳米乳疫苗还显著增强了干扰素-γ和白细胞介素-17A细胞因子细胞的免疫应答，提高了存活率，并减少了细菌定植。综上所述，我们的结果表明，这种新型纳米乳剂疫苗具有巨大的潜力，并且是有效的肌内全身和鼻粘膜免疫应答的强大发生器，而不需要额外的佐剂。因此，本研究为开发这种新型纳米乳液佐剂疫苗的未来策略提供了坚实的科学基础，以增强肌内全身和鼻粘膜免疫反应。
The Gram-positive bacterial pathogen methicillin-resistant Staphylococcus aureus (MRSA) can cause infections in the bloodstream, endocardial tissue, respiratory tract, culture-confirmed skin, or soft tissue. There are currently no effective vaccines, and none are expected to become available in the near future. An effective vaccine capable of eliciting both systemic and mucosal immune responses is also urgently needed. Here, we reported a novel oil-in-water nanoemulsion adjuvant vaccine containing an MRSA recombination protein antigen, Cremophor EL-35® as a surfactant, and propylene glycol as a co-surfactant. This nanoemulsion vaccine, whose average diameter was 31.34±0.49 nm, demonstrated good protein structure integrity, protein specificity, and good stability at room temperature for 1 year. The intramuscular systemic and nasal mucosal immune responses demonstrated that this nanoemulsion vaccine could improve the specific immune responses of immunoglobulin (Ig)G and related subclasses, such as IgG1, IgG2a, and IgG2b, as well as IgA, in the serum after Balb/c mice intramuscular immunization and C57 mice nasal immunization. Furthermore, this nanoemulsion vaccine also markedly enhanced the interferon-γ and interleukin-17A cytokine cell immune response, improved the survival ratio, and reduced bacterial colonization. Taken together, our results show that this novel nanoemulsion vaccine has great potential and is a robust generator of an effective intramuscular systemic and nasal mucosal immune response without the need for an additional adjuvant. Thus, the present study serves as a sound scientific foundation for future strategies in the development of this novel nanoemulsion adjuvant vaccine to enhance both the intramuscular systemic and nasal mucosal immune responses.